Depression

If you are suffering from a depressive episode, you may benefit from participating in one of our clinical trials, which offer you treatment with novel substances that have not yet reached market approval and can therefore not be prescribed otherwise.

Regarding major depressive disorder (MDD), we are currently performing the following clinical trials:

Escape TRD

A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor.

You might consider study participation if the following inclusion criteria apply:

  • You are currently suffering from a major depressive episode.
  • You are between 18 and 74 years of age.
  • At study entry, you have been treated with an SSRI or SNRI for a minimum of 6 weeks without achieving sufficient improvement.
  • You have received treatment with at least one, maximum five antidepressant substances during the current depressive episode without benefitting sufficiently.

Duration of Study: 36 weeks

We will gladly discuss further in- and exclusion criteria as well as study procedures during a personal meeting.

Boehringer MDD

A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial with a quetiapine arm to evaluate the efficacy, tolerability and safety of oral BI 1358894 in patients with Major Depressive Disorder with inadequate response to antidepressants.

You might consider study participation if the following inclusion criteria apply:

  • You have been diagnosed with severe depression.
  • You are between 18 and 65 years of age.
  • The current depressive episode has been going on for more than 8 weeks, but less than 12 months.
  • At study entry, you have been treated with a SSRI or SNRI for a minimum of 8 weeks.

Duration of Study: 6 weeks

We will gladly discuss further in- and exclusion criteria as well as study procedures during a personal meeting.

For further information, please contact our site staff:

Dinah Schramm, telephone number: 06131-17-6101,
 dinah.schramm@unimedizin-mainz.de

and/or

Ricarda Endler, telephone number: 06131-17-6102,
 ricarda.endler@unimedizin-mainz.de

or

or get in touch with us via our general e-mail address:
 SPE@unimedizin-mainz.de

University Medical Center Mainz
Study Center for Clinical Trials in Mental Disorders
Untere Zahlbacher Str. 8
55131 Mainz
Germany